The pharmacological rationale for treating vascular dementia with galantamine (Reminyl™)

International Journal of Clinical Practice, Supplement

Volumn , Issue 120, 2001, Pages 24-28

  Maelicke, A ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Alzheimer's disease; Cholinergic deficit; Galantamine; Nicotinic receptors; Vascular dementia

Indexed keywords

GALANTAMINE; SABELUZOLE;

ALZHEIMER DISEASE; BEHAVIOR DISORDER; CHOLINERGIC SYSTEM; COGNITIVE DEFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG USE; FUNCTIONAL DISEASE; HUMAN; MULTIINFARCT DEMENTIA; PRIORITY JOURNAL; REVIEW;

ACETYLCHOLINE; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DEMENTIA, VASCULAR; GALANTAMINE; HUMANS; NOOTROPIC AGENTS; RECEPTORS, CHOLINERGIC; RECEPTORS, NICOTINIC;

EID: 0034992051     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: A multicentre randomised controlled trial
2. Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease
3. Cerebrovascular dementia. Pathophysiology, diagnosis and treatment
4. The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinson's disease
5. Nicotinic receptors and neurodegenerative dementing diseases: Basic research and clinical implications
6. Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: Possible index of early neuropathology
7. The cholinergic hypothesis of geriatric memory dysfunction
8. Ageing: The cholinergic hypothesis of cognitive decline
9. The cholinergic system in Alzheimer's disease
10. Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease
11. Animal models of vascular dementia with emphasis on stroke-prone spontaneously hypertensive rats
12. Neurochemical profiles in cerebrospinal fluid of stroke-prone spontaneously hypertensive rats
13. Pathogenesis of vascular dementia in stroke-prone spontaneously hypertensive rats
14. Cholinergic changes in the hippocampus of stroke-prone spontaneously hypertensive rats
15. Changes in nicotinic acetylcholine receptor subunit mRNAs and nicotinic binding in spontaneously hypertensive stroke prone rats
16. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease
17. The neurochemistry of vascular dementia
18. Neurochemical abnormalities in vascular dementia
19. Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia
20. The pharmacotherapy of Alzheimer's disease based on the cholinergic hypothesis: An update
21. Separate and combined effects of the social drugs on psychomotor performance
22. Effects of post-trial administration of nicotine on human memory: Evaluating the conditions for improving memory
23. The effects of nicotine on attention, information processing, and working memory in patients with dementia of the Alzheimer type
24. New approach to drug therapy in Alzheimer's disease
25. Anti-dementia drugs
26. Agonist responses of neuronal nicotinic receptors are potentiated by a novel class of allosterically acting ligands
27. Galantamine is an allosterically potentiating ligand of the hu man alpha4beta2 nAChR
28. Pharmacological evaluation of novel Alzheimer's disease therapeutics: Acetylcholinesterase inhibitors related to galanthamine
29. Galantamine in AD - A 6-month randomized, placebo-controlled trial with a 6-month extension
30. A 5-month, randomized, placebo-controlled trial of galantamine in Alzheimer's disease
31. Nicotinic acetylcholine binding sites in Alzheimer's disease
32. Chronic treatment of old rats with donepezil or galantamine: Effects on memory, hippocampal plasticity and nicotinic receptors
33. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease